Vireo Growth (VREOF) Non Operating Income (2020 - 2026)
Vireo Growth's (VREOF) quarterly Non Operating Income came in at -$13.2 million in Q1 2026, down 94.12% year-on-year from -$224.4 million in Q1 2025, and down 132.77% quarter-over-quarter from $40.3 million in Q4 2025.
Vireo Growth (VREOF) Non Operating Income (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Non Operating Income across 7 years of filings, most recently posting -$13.2 million for Q1 2026.
- Non Operating Income for Q1 2026 came in at -$13.2 million, down 94.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.7 million (up 1550.89% YoY), and the FY2025 annual result was $11.6 million, up 1127.09% from the prior year.
- Non Operating Income came in at -$13.2 million for Q1 2026 at Vireo Growth, down from $40.3 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $40.3 million in Q4 2025 to a low of -$13.2 million in Q1 2026.
- The 5-year median for Non Operating Income is $45518.0 (2022), against an average of $1.6 million.
- Peak annual rise in Non Operating Income reached 5805.03% in 2024, while the deepest fall reached 1948.57% in 2024.
- Vireo Growth's Non Operating Income stood at $45518.0 in 2022, then jumped by 3370.77% to $1.6 million in 2023, then soared by 1222.33% to $20.9 million in 2024, then soared by 92.82% to $40.3 million in 2025, then plunged by 132.77% to -$13.2 million in 2026.
- The last three Non Operating Income figures came in at -$13.2 million (Q1 2026), $40.3 million (Q4 2025), and $983080.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -216.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 20.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -7.50 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -504,111.66 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 53.40 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -13.65 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -23.23 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 5.71 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | -13.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.20 Mn |
| Dec 31, 2025 | 40.28 Mn |
| Sep 30, 2025 | 983,080.00 |
| Jun 30, 2025 | -407,673.00 |
| Mar 31, 2025 | -6.80 Mn |
| Dec 31, 2024 | 20.89 Mn |
| Sep 30, 2024 | -6.39 Mn |
| Jun 30, 2024 | -6.02 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.58 Mn |
| Sep 30, 2023 | 345,824.00 |
| Jun 30, 2023 | 5.80 Mn |
| Mar 31, 2023 | 22,313.00 |
| Dec 31, 2022 | 45,518.00 |
| Sep 30, 2022 | -7.59 Mn |
| Jun 30, 2022 | -5.45 Mn |
| Mar 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | 5.32 Mn |
| Sep 30, 2021 | -2.18 Mn |
| Jun 30, 2021 | -2.85 Mn |